| Objective:To investigate erlotinib which belongs to new targeted therapy drugs,and its influence on human ovarian cancer cell line SKOV3 in vitroand.Method:Ovarian cancer cell line SKOV3 were culitivated in vitro under the irritation of erlotinib with different concentrations (0、10、20、30、 40、50、60、70、80)μ mol/L for 24h、48h and 72h.The inhibition rates were detected by MTT array, and cells IC50was calculated; the cell cycle and Apoptosis of SKOV3 cells exposed to erlotinib with different concentrations (0、20、40、80) μ mol/L was analyzed by flow cytometry.Result:1. The erlotinib obviously inhibited the proliferation of SKOV3 cells in a time and dose dependent manner, compared with the control groups, the difference was statistically significant (P<0.05).Cells in 24h,48h,72h and the number of IC50 was 22.396 μ mol/L,15.064 μ mol/L,11.177 μ mol/L。2. With the increase of concentration of erlotinib applied to SKOV3 cells, normal tummer cells gradually decreased, early apoptotic and late apoptotic cells showed an upward trend,comparisons were made among groups with different concentrations, the difference was statistically significant(P<0.05).3. With the increase of concentration of erlotinib applied to SKOV3 cells, the amount of GO/G1 phase cell proportion saw a significantly increase trend, comparisons were made among groups with different concentrations,the difference was statistically significant(P<0.05), while the amount of G2/M issue of cell proportion saw a significantly decrease trend,comparisons were made among groups with different concentrations,the difference was statistically significant(P<0.05).Conclusion:1. Erlotinib can obviously inhibit SKOV3 cell proliferation and induce cell apoptosis, besides, it can be effctive to block the cell cycle of SKOV3 in G0/G1 phase, in this way,it is supposed be provided as a theoretical basis in treatment of ovarian cancer. |
PDF Full Text Request